// App-Quantinova.ai

FRI0470 (2018) : A phase 2 study of safety and efficacy of lenabasum (JBT-101, a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis

Researchers

Presenter

  • V.P. Werth

Principal Investigators

  • E. Hejazi

  • S.M. Pena

  • J.S. Haber

  • J. Okawa

  • R. Feng

  • K. Gabre

  • J.S. Concha

  • C. Cornwall

  • N. Dgetluck

  • S. Constantine

  • B. White

Medical Centers

  • Philadelphia Veteran Affairs Medical Center

  • University of Pennsylvania, Philadelphia, PA

  • Corbus Pharmaceuticals, Norwood, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Juvenile dermatomyositis

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Ajulemic acid

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT02466243

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved